Literature DB >> 20512990

Intrahepatic peripheral cholangiocarcinoma in cirrhosis patients may display a vascular pattern similar to hepatocellular carcinoma on contrast-enhanced ultrasound.

Ramón Vilana1, Alejandro Forner, Luis Bianchi, Angeles García-Criado, Jordi Rimola, Carlos Rodríguez de Lope, María Reig, Carmen Ayuso, Concepció Brú, Jordi Bruix.   

Abstract

UNLABELLED: The aim of this study was to describe the imaging features by contrast-enhanced ultrasound (CEUS) of intrahepatic cholangiocarcinoma (ICC) in cirrhosis patients. We registered the CEUS images of cirrhosis patients with histologically confirmed ICC. In all cases magnetic resonance imaging (MRI) was done to confirm the diagnosis and/or staging purposes. A total of 21 patients met all the criteria to be included in the study. The median nodule size was 32 mm. All nodules showed contrast enhancement at arterial phase; in 10 cases it was homogeneous and in 11 cases peripheral (rim-like). All nodules displayed washout during the venous phases; it appeared during the first 60 seconds in 10 nodules, between 60-120 seconds in five cases, and in six cases after 2 minutes. Ten nodules (five larger than 2 cm) displayed homogeneous contrast uptake followed by washout and they correspond to the specific pattern of hepatocellular carcinoma according to the American Association for the Study of Liver Diseases criteria. However, none of these lesions displayed washout on MRI.
CONCLUSION: CEUS should not be used as the sole imaging technique for conclusive hepatocellular carcinoma diagnosis and if the MRI does not display the diagnostic vascular pattern, a confirmatory biopsy is mandatory.

Entities:  

Mesh:

Substances:

Year:  2010        PMID: 20512990     DOI: 10.1002/hep.23600

Source DB:  PubMed          Journal:  Hepatology        ISSN: 0270-9139            Impact factor:   17.425


  80 in total

Review 1.  Cirrhosis in hepatitis C virus-infected patients: a review for practitioners new to hepatitis C care.

Authors:  Andrew J Muir
Journal:  Top Antivir Med       Date:  2014 Sep-Oct

2.  Multidisciplinary Canadian consensus recommendations for the management and treatment of hepatocellular carcinoma.

Authors:  M Sherman; K Burak; J Maroun; P Metrakos; J J Knox; R P Myers; M Guindi; G Porter; J R Kachura; P Rasuli; S Gill; P Ghali; P Chaudhury; J Siddiqui; D Valenti; A Weiss; R Wong
Journal:  Curr Oncol       Date:  2011-10       Impact factor: 3.677

3.  Differentiation of intrahepatic mass-forming cholangiocarcinoma from hepatocellular carcinoma on gadoxetic acid-enhanced liver MR imaging.

Authors:  Rihyeon Kim; Jeong Min Lee; Cheong-Il Shin; Eun Sun Lee; Jeong Hee Yoon; Ijin Joo; Seong Ho Kim; Inpyeong Hwang; Joon Koo Han; Byung Ihn Choi
Journal:  Eur Radiol       Date:  2015-09-15       Impact factor: 5.315

Review 4.  Critical appraisal of Chinese 2017 guideline on the management of hepatocellular carcinoma.

Authors:  Di-Yang Xie; Zheng-Gang Ren; Jian Zhou; Jia Fan; Qiang Gao
Journal:  Hepatobiliary Surg Nutr       Date:  2017-12       Impact factor: 7.293

5.  From liver cirrhosis to HCC.

Authors:  Luigi Bolondi; Laura Gramantieri
Journal:  Intern Emerg Med       Date:  2011-10       Impact factor: 3.397

Review 6.  Cholangiocarcinoma 2020: the next horizon in mechanisms and management.

Authors:  Jesus M Banales; Jose J G Marin; Angela Lamarca; Pedro M Rodrigues; Shahid A Khan; Lewis R Roberts; Vincenzo Cardinale; Guido Carpino; Jesper B Andersen; Chiara Braconi; Diego F Calvisi; Maria J Perugorria; Luca Fabris; Luke Boulter; Rocio I R Macias; Eugenio Gaudio; Domenico Alvaro; Sergio A Gradilone; Mario Strazzabosco; Marco Marzioni; Cédric Coulouarn; Laura Fouassier; Chiara Raggi; Pietro Invernizzi; Joachim C Mertens; Anja Moncsek; Sumera Rizvi; Julie Heimbach; Bas Groot Koerkamp; Jordi Bruix; Alejandro Forner; John Bridgewater; Juan W Valle; Gregory J Gores
Journal:  Nat Rev Gastroenterol Hepatol       Date:  2020-06-30       Impact factor: 46.802

Review 7.  Diagnosis and treatment of hepatocellular carcinoma: An update.

Authors:  Javier Tejeda-Maldonado; Ignacio García-Juárez; Jonathan Aguirre-Valadez; Adrián González-Aguirre; Mario Vilatobá-Chapa; Alejandra Armengol-Alonso; Francisco Escobar-Penagos; Aldo Torre; Juan Francisco Sánchez-Ávila; Diego Luis Carrillo-Pérez
Journal:  World J Hepatol       Date:  2015-03-27

8.  Distinguishing intrahepatic cholangiocarcinoma from hepatocellular carcinoma in patients with and without risks: the evaluation of the LR-M criteria of contrast-enhanced ultrasound liver imaging reporting and data system version 2017.

Authors:  Fei Li; Qing Li; Yubo Liu; Jing Han; Wei Zheng; Yini Huang; Xueyi Zheng; Longhui Cao; Jian-Hua Zhou
Journal:  Eur Radiol       Date:  2019-07-11       Impact factor: 5.315

9.  Effect of contrast-enhanced ultrasound on differential diagnosis of intrahepatic cholangiocarcinoma and arterial phase enhanced hepatic inflammatory lesions.

Authors:  Shanshan Yin; Qiuli Cui; Kun Yan; Wei Yang; Wei Wu; Liping Bao; Minhua Chen
Journal:  Chin J Cancer Res       Date:  2017-06       Impact factor: 5.087

10.  Contrast-enhanced ultrasound appearances of enhancement patterns of intrahepatic cholangiocarcinoma: correlation with pathological findings.

Authors:  Francesco Loria; Giuseppe Loria; Salvatore Basile; Giuseppe Crea; Luciano Frosina; Isidoro Di Carlo
Journal:  Updates Surg       Date:  2014-05-07
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.